Colorectal cancer natural history
Jump to navigation
Jump to search
|
Colorectal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Colorectal cancer natural history On the Web |
|
American Roentgen Ray Society Images of Colorectal cancer natural history |
|
Risk calculators and risk factors for Colorectal cancer natural history |
To view the natural history of familial adenomatous polyposis (FAP), click here
To view the natural history of hereditary nonpolyposis colorectal cancer (HNPCC), click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Saarah T. Alkhairy, M.D.; Elliot B. Tapper, M.D.; Roukoz A. Karam, M.D.[3]
Overview
Most colorectal cancer (CRC) develops slowly, over roughly 10–15 years, from a resectable precursor lesion through the chromosomal instability (adenoma–carcinoma), serrated, or mismatch repair–deficient pathways. This long window is the biologic basis for screening and polypectomy.[1][2] Only about 3–5% of adenomas ever progress to cancer.[3] Untreated invasive disease spreads to regional lymph nodes and then hematogenously, chiefly to the liver.[4]
About 15–40% of patients present as a surgical emergency, most often from obstruction or perforation, and emergency presentation independently predicts worse survival.[5][6]
Stage at diagnosis is the dominant prognostic factor. Five-year relative survival exceeds 90% for localized disease and is about 12–16% for distant disease.[7] Tumor sidedness, histology, preoperative carcinoembryonic antigen (CEA), and molecular status (MMR/MSI, KRAS, BRAF) refine prognosis further.[8]
Natural History, Complications, and Prognosis
Natural History
Precursor Lesions and Carcinogenic Pathways
| Pathway | Approximate share of CRC | Key molecular events | Clinical behavior |
|---|---|---|---|
| Chromosomal instability (CIN; adenoma–carcinoma sequence) | ~70% | Inactivating APC mutation with Wnt/β-catenin activation, followed by KRAS activation and TP53 loss[2] | Normal mucosa → adenoma → carcinoma over an estimated 10–15 years[2][1] |
| Serrated neoplasia pathway | ~10–20%; up to ~30% may arise from clinically significant serrated polyps | BRAF mutation and CpG island methylator phenotype (CIMP); may yield microsatellite-stable or MSI-high cancer[9] | Sessile serrated lesions transition to cancer at <1% per year[9] |
| Mismatch repair–deficient (dMMR/MSI-high) | ~15% | Sporadic (MLH1 promoter hypermethylation) or germline (Lynch syndrome)[1] | Accelerated progression; cancer can develop within a few years[2] |
- People with synchronous adenoma and clinically significant serrated polyps may have both pathways active. They have a higher risk of advanced neoplasia at follow-up colonoscopy than people with adenomas alone.[10]
- Inherited syndromes (familial adenomatous polyposis, Lynch syndrome) are covered in their own microchapters.
Progression of Precursor Lesions
- CISNET modeling estimates 1–2 decades from normal mucosa to CRC.[9]
- Most adenomas never become malignant within a normal lifespan. Only about 3–5% progress to cancer.[3][11]
- Size and advanced histology are the main drivers of progression. Once an adenoma reaches ≥10 mm, cumulative CRC risk is about 1% at 1 year, 2.5% at 5 years, and 8% at 10 years.[9]
- Tumor-associated chromosomal instability has been proposed as an independent predictor of adenoma-to-carcinoma progression. It is investigational and not validated for routine use.[12]
Invasive and Metastatic Disease
- Untreated CRC invades through the bowel wall, spreads to regional lymph nodes, and disseminates hematogenously.
- The liver is the dominant metastatic site because of portal venous drainage. Lung, peritoneum, and bone follow.[4]
- Dissemination can occur early, while the primary tumor is still small. Metastatic disease is the principal determinant of survival.[4]
- Metastases may be synchronous (present at diagnosis) or metachronous (arising after primary treatment). Most recurrences after resection appear within the first 5 years.[4]
Symptomatic Course
Symptoms usually appear only once the tumor is advanced. Symptomatic patients have worse outcomes than patients whose cancer is found by screening.[13]
- Right-sided (cecal/ascending) tumors tend to bleed occultly. They often present with iron deficiency anemia and related fatigue, dyspnea, or palpitations.[13]
- Distal tumors more often cause overt rectal bleeding.[13]
- Rectosigmoid tumors, where the lumen is narrower, more often cause altered bowel habits and obstructive symptoms. These include crampy pain, distension, constipation, and paradoxical overflow diarrhea.[13]
- Unintentional weight loss is reported in up to half of symptomatic patients. Advanced disease can cause cancer cachexia.[13]
- Several analyses have not found that diagnostic delay in symptomatic patients correlates strongly with stage or survival.[13][14]
Complications
Emergency Presentation
About 15–40% of CRC presents as a surgical emergency, most often obstruction or perforation.[5] About 20% of patients with rectal cancer present with emergency symptoms.[15]
Emergency presentation independently predicts worse survival. Five-year net survival is about 46% after emergency presentation versus about 65% after elective presentation.[6] Emergency presentation is associated with lymphovascular invasion, perineural invasion, poor differentiation, and advanced stage.[15]
| Complication | Frequency | Prognostic significance |
|---|---|---|
| Obstruction | ~8–20%; more common with left-sided tumors[5] | NCCN high-risk feature in colon cancer[5] |
| Perforation | ~3–10%[5] | Occurs at the tumor or as a proximal "blowout" from closed-loop obstruction. Upstages disease and raises peritoneal carcinomatosis risk. Worse recurrence-free survival than obstruction (adjusted HR for recurrence ~3.7 in one series).[5] Mortality reaches ~65% for rectal tumor–related perforation.[16] |
| Gastrointestinal bleeding | Chronic occult bleeding is common | Chronic anemia usually does not change surgical timing.[17] |
Contemporary best-practice reviews still individualize emergency management because head-to-head data are limited.[18]
Other Complications
- Fistula formation (e.g., colovesical, colovaginal) and local invasion of adjacent organs.
- Recurrence can be local, regional, or distant (mainly liver and lung). Most recurrences occur within 5 years.[4]
- Treatment-related morbidity includes anastomotic leak, stoma-related problems (permanent stoma is more common in rectal cancer), chemotherapy toxicity, and radiation effects. Bevacizumab specifically increases bowel perforation risk.[17] Detailed toxicity profiles are covered in the treatment microchapters.
Prognosis
Stage at Diagnosis
Stage is the strongest predictor of survival.
| Stage | 5-year relative survival, United States (SEER)[7] | 5-year net survival, population-based colon cancer cohort[6] |
|---|---|---|
| All stages combined | ~64% (rectum ~67%; colon ~63%) | — |
| Stage I / localized | >90% (colon and rectum) | ~96% (stage I) |
| Stage II | — | ~87% |
| Stage III / regional | ~70% (regional) | ~61% |
| Stage IV / distant | ~12% (colon); ~16% (rectum) | <10% |
- The higher overall survival for rectal cancer partly reflects a larger share of localized rectal disease at diagnosis.[7]
- Across seven high-income countries (ICBP SURVMARK-2), 5-year net survival was about 59–71% for colon cancer and 62–71% for rectal cancer. The widest international variation was in regional and distant disease.[19]
- Survival trends in Japan (CONCORD-3) are consistent with these patterns.[20]
- Stage III paradox: in granular AJCC substage data, some stage IIIA cancers have better survival than stage IIB/IIC cancers. This reflects the benefit of adjuvant therapy in node-positive disease and understaging of high-risk node-negative tumors. Substage-specific survival figures should be interpreted with this in mind.
Clinicopathologic Prognostic Factors
- Tumor sidedness: left-sided colon cancer has better 5-year net survival than right-sided (~66% vs ~59%). The difference is most evident in metastatic disease.[6]
- Histology: poor differentiation, mucinous histology, and signet-ring histology carry a worse prognosis.[8]
- Lymph node yield: examining ≥12 nodes is recommended for accurate staging. Inadequate yield risks understaging node-negative disease. The number of negative nodes is prognostic in stage IIIB/IIIC.[8]
- Tumor deposits, lymphovascular invasion, and perineural invasion are independent adverse factors.[8]
- Obstruction and perforation are NCCN high-risk features in colon cancer.[5][8]
Carcinoembryonic Antigen (CEA)
- Preoperative CEA gives prognostic information independent of stage. It should be measured before resection to establish a baseline for surveillance. An elevated preoperative value predicts a worse outcome.[21]
- In colorectal liver metastases, high CEA before and after hepatectomy independently predicts poorer overall and recurrence-free survival.[22][23]
- CEA may be a less reliable prognostic marker in younger patients. Circulating tumor DNA (ctDNA) is an emerging, complementary biomarker but is not yet standard for prognostication.[24]
Molecular Prognostic Markers
Universal mismatch repair (MMR)/microsatellite instability (MSI) testing is recommended for all newly diagnosed CRC.[8]
| Marker | Prognostic implication | Clinical note |
|---|---|---|
| dMMR/MSI-high | Favorable prognosis after adjustment for stage[8] | Stage II MSI-high colon cancer has a good prognosis and does not benefit from adjuvant fluorouracil monotherapy.[8] |
| KRAS mutation | In resected stage II/III disease, independently predicts worse overall survival (HR ~1.25–1.27). The effect is largely confined to microsatellite-stable (MSS) tumors.[25][26] | Any KRAS/NRAS mutation predicts lack of benefit from anti-EGFR antibodies (cetuximab, panitumumab). See the treatment microchapters.[8] |
| BRAF V600E | In resected stage II/III disease, independently predicts worse overall survival (HR ~1.43–1.49), mainly in MSS tumors.[25][26] | In MSI-high tumors, KRAS/BRAF mutations do not carry the same adverse effect. MSI-high tumors with these mutations have had better outcomes than MSS wild-type tumors.[27] |
Metastatic Disease and Liver Metastases
- Median survival for CRC with liver metastasis is about 12 months in population-based data. It falls sharply as additional metastatic sites are involved.[28]
- Adverse factors in hepatic metastatic disease include:[29][23]
- Synchronous presentation
- Short disease-free interval
- Multiple and large lesions
- High CEA
- Extrahepatic (lung, bone) metastases
Early-Onset Colorectal Cancer
Early-onset CRC (EOCRC), diagnosed before age 50, is rising and is increasingly viewed as a biologically distinct entity.[30]
- Presentation: predominantly distal colon and rectum (>70% left-sided), more often at an advanced stage, with more poorly differentiated, mucinous, or signet-ring histology.[14][31]
- Symptoms: symptoms precede 70–95% of diagnoses. Rectal bleeding, abdominal pain, and changed bowel habits are often attributed to benign disease.[14][31]
- Somatic profile: more MSI-high and TP53/CTNNB1 alterations, and fewer APC, KRAS, and BRAF mutations, than late-onset disease.[32]
- Prognosis: stage-matched survival is broadly comparable to late-onset disease, so outcomes are driven mainly by stage rather than age.[32] Some cohorts report similar or shorter survival overall, largely reflecting later stage at diagnosis.[30]
- Risk factors and germline evaluation in EOCRC are covered in the risk factors and genetics microchapters.
Areas of Uncertainty
- Which individual adenomas will progress cannot yet be predicted. Chromosomal instability and proteomic or molecular signatures are promising but not validated for routine use.[3][12]
- Whether EOCRC carries an independently worse prognosis, or warrants distinct treatment paradigms, remains unresolved.[30][32]
- Optimal emergency management of obstructing CRC (stent vs diverting stoma vs upfront resection) lacks definitive head-to-head data. Recommendations rest on moderate- to low-quality evidence and local expertise.[17][18]
- The prognostic value of CEA in young patients is uncertain. ctDNA is not yet standard for prognostication.[24]
- The stage III substage paradox reflects the limits of anatomic staging without molecular refinement.
Clinical Pearls
- The roughly decade-long adenoma-to-carcinoma window is the biologic basis for screening and polypectomy-based prevention.[2]
- Iron deficiency anemia in an adult, especially from occult bleeding, should prompt evaluation for right-sided colon cancer.[13]
- Order MMR/MSI testing on every new CRC. Missing it forfeits Lynch syndrome detection, immunotherapy eligibility, and stage II treatment refinement.[8]
- Interpret KRAS/BRAF prognosis in the context of MSI status. Their adverse effect is largely confined to MSS tumors.[27]
- Measure CEA before resection.[21]
- Avoid colonic stenting when anti-angiogenic therapy is planned or when perforation is present or suspected. Avoid stenting distal rectal tumors.[17][16]
- Do not proceed directly to emergent resection of locally advanced rectal cancer when diversion would preserve neoadjuvant therapy.[16]
- In a patient under 50 with rectal bleeding or changed bowel habits, do not reflexively attribute symptoms to hemorrhoids or irritable bowel syndrome. Arrange colonoscopy.[14]
References
- ↑ 1.0 1.1 1.2 Dekker E, Tanis PJ, Vleugels JLA; et al. (2019). "Colorectal cancer". Lancet. PMID 31631858.
- ↑ 2.0 2.1 2.2 2.3 2.4 Nguyen LH, Goel A, Chung DC (2020). "Pathways of colorectal carcinogenesis". Gastroenterology. PMID 31554014.
- ↑ 3.0 3.1 3.2 Bech JM, Terkelsen T, Bartels AS; et al. (2023). "Proteomic profiling of colorectal adenomas identifies a predictive risk signature for development of metachronous advanced colorectal neoplasia". Gastroenterology. 165 (1): 121–132.e5. doi:10.1053/j.gastro.2023.03.208.
- ↑ 4.0 4.1 4.2 4.3 4.4 Cañellas-Socias A, Sancho E, Batlle E (2024). "Mechanisms of metastatic colorectal cancer". Nat Rev Gastroenterol Hepatol. 21 (9): 609–625. doi:10.1038/s41575-024-00934-z. PMID 38806657 Check
|pmid=value (help). - ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 Yang KM, Jeong MJ, Yoon KH, Jung YT, Kwak JY (2022). "Oncologic outcome of colon cancer with perforation and obstruction". BMC Gastroenterol. 22 (1): 247. doi:10.1186/s12876-022-02319-5.
- ↑ 6.0 6.1 6.2 6.3 Brindel P, Fournier E, Chappuis PO; et al. (2026). "Survival of colon cancer in a population-based cohort study: a comprehensive analysis of location of the primary tumor". Cancer Med. doi:10.1002/cam4.72140.
- ↑ 7.0 7.1 7.2 Wagle NS, Nogueira L, Devasia TP; et al. (2025). "Cancer treatment and survivorship statistics, 2025". CA Cancer J Clin. 75 (4): 308–340. doi:10.3322/caac.70011. PMID 40445120 Check
|pmid=value (help). - ↑ 8.00 8.01 8.02 8.03 8.04 8.05 8.06 8.07 8.08 8.09 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer (Principles of Pathologic and Molecular Review). 2026.
- ↑ 9.0 9.1 9.2 9.3 Sullivan BA, Lieberman DA (2024). "Colon polyp surveillance: separating the wheat from the chaff". Gastroenterology. 166 (5): 743–757. doi:10.1053/j.gastro.2023.11.305. PMID 38437919 Check
|pmid=value (help). - ↑ Laven-Law G, Symonds EL, Simpson K, Coats M, De Silva M, Hollington P, Cock C, Wassie MM (2026). "Risk of advanced colorectal neoplasia at follow-up colonoscopy after synchronous adenoma and clinically significant serrated polyp". Clin Gastroenterol Hepatol.
- ↑ Garber JJ, Chung DC (2022). "Polyps of the colon and rectum". Yamada's Textbook of Gastroenterology (7th ed.).
- ↑ 12.0 12.1 Li H, Yang F, Bai B, et al. Tumor associated chromosomal instability drives colorectal adenoma to adenocarcinoma progression. Sci Rep. 2025.
- ↑ 13.0 13.1 13.2 13.3 13.4 13.5 13.6 Luther J, Chan AT (2022). "Malignant tumors of the colon". Yamada's Textbook of Gastroenterology (7th ed.).
- ↑ 14.0 14.1 14.2 14.3 Burnett-Hartman AN, Lee JK, Demb J, Gupta S (2021). "An update on the epidemiology, molecular characterization, diagnosis, and screening strategies for early-onset colorectal cancer". Gastroenterology. 160 (4): 1041–1049. doi:10.1053/j.gastro.2020.12.068. PMID 33417940 Check
|pmid=value (help). - ↑ 15.0 15.1 Pajola M, Fugazzola P, Cobianchi L, Frassini S, Ghaly A, Bianchi C, Ansaloni L (2025). "Surgical emergencies in rectal cancer: a narrative review". J Clin Med. 14 (1): 126. doi:10.3390/jcm14010126.
- ↑ 16.0 16.1 16.2 Invalid
<ref>tag; no text was provided for refs namedYou2020 - ↑ 17.0 17.1 17.2 17.3 Invalid
<ref>tag; no text was provided for refs namedpmid34775402 - ↑ 18.0 18.1 Tejedor P, Pastor C, Caycedo-Marulanda A, Whiteford M, McLemore EC, Sylla P, Boutros M, Alkhamesi NA (2026). "Clinical spotlight review: best practices for the management of colorectal cancer in the emergency and acute care setting". Surg Endosc. 40 (7): 5459–5467. doi:10.1007/s00464-026-12880-9.
- ↑ Araghi M, Arnold M, Rutherford MJ; et al. (2021). "Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project)". Gut. PMID 32482683 Check
|pmid=value (help). - ↑ Oki I, Matz M, Sugiyama H; et al. (2026). "Trends in net survival for cancers of the colon and rectum in Japan, 2000–14 (CONCORD-3)". Jpn J Clin Oncol. PMID 41859884 Check
|pmid=value (help). - ↑ 21.0 21.1 Locker GY, Hamilton S, Harris J; et al. (2006). "ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer". J Clin Oncol. 24 (33): 5313–5327. doi:10.1200/JCO.2006.08.2644. PMID 17060676.
- ↑ Yuan C, Zeng L, Duan H; et al. (2024). "Meta-analysis of the prognostic value of serum CEA in colorectal cancer liver metastases after hepatectomy". Eur J Cancer Prev. PMID 37997904 Check
|pmid=value (help). - ↑ 23.0 23.1 Kobayashi K, Ono Y, Kitano Y; et al. (2023). "Prognostic impact of tumor markers (CEA and CA19-9) on patients with resectable colorectal liver metastases". Ann Surg Oncol. PMID 37365416 Check
|pmid=value (help). - ↑ 24.0 24.1 Grob et al. [Title not available]. J Surg Oncol. 2026.
- ↑ 25.0 25.1 Formica V, Sera F, Cremolini C; et al. (2022). "KRAS and BRAF mutations in stage II and III colon cancer: a systematic review and meta-analysis". J Natl Cancer Inst. PMID 34542636 Check
|pmid=value (help). - ↑ 26.0 26.1 Kang D, Li J, Li Y, Xu J, Yang J, Zhang Z (2025). "Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: a retrospective study and meta-analysis". PLoS One. doi:10.1371/journal.pone.0320783.
- ↑ 27.0 27.1 Domingo E, Camps C, Kaisaki PJ; et al. (2018). "Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series". Lancet Gastroenterol Hepatol. 3 (9): 635–643. doi:10.1016/S2468-1253(18)30117-1.
- ↑ Tang M, Wang H, Cao Y, et al. Nomogram for predicting occurrence and prognosis of liver metastasis in colorectal cancer. Int J Colorectal Dis. 2021.
- ↑ Liu C, Hu C, Huang J; et al. (2021). "A prognostic nomogram of colon cancer with liver metastasis: a study of the US SEER database and a Chinese cohort". Front Oncol. doi:10.3389/fonc.2021.591009. PMID 33738248 Check
|pmid=value (help). - ↑ 30.0 30.1 30.2 Jayakrishnan T, Ng K (2025). "Early-onset gastrointestinal cancers: a review". JAMA. doi:10.1001/jama.2025.10218. PMID 40674064 Check
|pmid=value (help). - ↑ 31.0 31.1 Catani G, O'Connor JM, Spinelli A, Perea J (2026). "Early-onset colorectal cancer: a comprehensive review reframing hypotheses and defining research priorities". Int J Colorectal Dis. 41 (1). doi:10.1007/s00384-026-05145-3.
- ↑ 32.0 32.1 32.2 Huang QS, Yu XZ, Zhao R; et al. (2025). "Clinicopathological characteristics and biomarker alterations in early-onset vs. late-onset colorectal cancer: a systematic review and meta-analysis". Int J Surg. PMID 40956186 Check
|pmid=value (help).